Product Information |
Product name |
Empagliflozin |
CAS No. |
864070-44-0 |
Molecular Formula |
C23H27ClO7 |
Molecular Weight |
450.91 |
Quality Standard |
99.5% up by HPLC, Medical Grade |
Appearance |
White powder |
COA of Empagliflozin |
ITEMS |
||
White to off-White Powder |
Complies |
|
HPLC |
Complies |
|
150 ~ 155 ℃ |
152.0 ~ 154.0 ℃ |
|
≤0.5% |
0.3% |
|
≤0.1% |
Complies |
|
≤10ppm |
Complies |
|
≤0.5% |
0.32% |
|
+15 ~ +21 |
+19.5 |
|
8-12mg/ 100ml |
9mg/ 100ml |
|
soluble in methanol and DCM |
Conformed |
|
Total impurities ≤0.5% Single impurity(max)≤0.1% |
0.23% 0.04% |
|
≤0.15% |
0.09% |
|
D90<20μ m |
Complies |
|
≥99.5% |
99.86% |
|
Residual solvents |
Ethyl acetate≤0.5% |
0.20% |
Dichloromethane≤0.6% |
ND |
|
Ethyl alcohol≤0.5% |
0.03% |
|
Methanol≤0.3% |
ND |
|
ACN≤0.041% |
ND |
|
Tetrahydrofurans≤0.072% |
0.04% |
|
Methylbenzene≤0.089% |
0.06% |
|
Conclusion |
Complies with specification. |
Usage |
Function of Empagliflozin
Empagliflozin tablet is a new type of hypoglycemic drug, which can reduce the blood sugar level of patients and protect the liver and kidney function of patients. In addition, it also has a certain protective effect on the cardiovascular system of patients. When Empagliflozin tablets are used alone, patients often have lower blood sugar levels than before, and hypoglycemia rarely occurs. It is recommended that patients pay attention to monitoring the blood glucose level during the oral administration of Empagliflozin tablets. If Empagliflozin is used alone, the blood sugar level is not lowered well, it can also be combined with metformin or acarbose or other Hypoglycemic drugs.
*Products under the patent are only for R&D use